Beam Therapeutics Sues Chinese Rivals Over Alleged Theft of Base Editing Secrets

Key points

• Beam Therapeutics filed a complaint on Sept. 25 in the U.S. District Court for the District of Massachusetts, naming YolTech Therapeutics, Serapha Bio, and former scientist Zi Jun 'Emma' Wang as defendants.
• The lawsuit alleges that Wang, who worked for Beam from March 2021 to January 2022, secretly founded YolTech in July 2021 while still employed, using Beam's trade secrets to develop a base editing therapy for alpha-1 antitrypsin deficiency (AATD).
• Beam claims Wang accessed electronic lab notebooks and technical records at night and on weekends, retrieving data she had never previously accessed, to build the foundation for YolTech's candidate, YOLT-202.
• YolTech later licensed its AATD therapy to Serapha Bio, which launched in June 2026 with $230 million in funding from RA Capital Management and RTW Investments, and is developing the drug as SERP-01.
• Beam argues that SERP-01 and its own lead candidate, BEAM-302, are 'strikingly similar' because both target the same mutation in the SERPINA1 gene and swap an adenine for a guanine using base editing technology.
• Serapha Bio's chief corporate affairs officer stated that the company 'categorically refutes' Beam's claims and will vigorously defend itself, while YolTech has not yet responded to requests for comment.

Background

This dispute occurs amid rising tensions between American and Chinese biotech firms over intellectual property. Beam previously prevailed in a patent dispute against Prime Medicine regarding AATD therapies. The current case highlights ongoing concerns about data security and trade secret misappropriation in the gene editing sector, where base editing is a critical technology for treating rare diseases like AATD.

How outlets are covering it

Fierce Biotech and BioPharma Dive emphasize the technical similarities between Beam's BEAM-302 and the rival SERP-01, noting that both target the same nucleotide change in the SERPINA1 gene. They highlight the specific allegations of off-hours access to Beam's electronic lab notebooks. STAT frames the lawsuit within the broader context of escalating U.S.-China biotech tensions, while noting that Serapha has denied the claims. Endpoints News provides the initial report but is limited by a paywall, offering fewer details than the secondary sources.

Why it matters

The outcome of this lawsuit could set a precedent for intellectual property protection in the rapidly growing gene editing industry. If Beam succeeds, it may impact how biotech companies manage employee data and trade secrets, particularly in cross-border collaborations. The case also affects the development timelines and commercial viability of SERP-01, a therapy aimed at a rare disease with limited treatment options.

What to watch

Beam is seeking court intervention to stop the alleged misuse of its trade secrets and recover damages. Serapha Bio plans to begin a Phase 2/3 trial of SERP-01 later in 2026 or early 2027, regardless of the lawsuit. The legal proceedings will determine whether the rival therapy can proceed or if it must be halted due to alleged misappropriation of Beam's proprietary technology.